NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
TG Therapeutics, Inc. (TGTX)
Class Period: June 4, 2018 - September 25, 2018
Lead Plaintiff Deadline: December 3, 2018
Join the action: https://www.zlk.com/pslra-1/tg-therapeutics-inc-loss-form?wire=3
About the lawsuit: TG Therapeutics, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and as a result, was able to gain an understanding as to the efficacy of the combination therapy; (2) as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal and as a result, the Company would not be able to seek accelerated approval; and (3) given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival.
To learn more about the TG Therapeutics, Inc. class action contact email@example.com.
Trevena, Inc. (TRVN)
Class Period: May 2, 2016 - October 9, 2018
Lead Plaintiff Deadline: December 10, 2018
Join the action: https://www.zlk.com/pslra-1/trevena-inc-loss-form?wire=3
About the lawsuit: Throughout the class period, Trevena, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) during its meetings with the FDA prior to the start of the Class Period, Trevena had been advised that the FDA did not agree with certain aspects of the design of the Phase III clinical trial of Olinvo, including the proposed dosing, the proposed primary endpoint and the proposed non-inferiority margin for comparing morphine to Olinvo; (b) unless Trevena demonstrated that Olinvo was at least equally effective to morphine in treating post-operative pain in the Phase III clinical trial, the FDA would be unwilling to consider any secondary benefits Olinvo might confer in terms of reduced opioid-related adverse effects ("ORAEs"); (c) the FDA disagreed with how the safety data was being compiled in the Phase II clinical trial; (d) because the FDA did not agree with major tenants of the design of the Phase III clinical trial, it was highly unlikely that the FDA would find the data obtained from that clinical trial sufficient to support Trevena’s NDA; (e) because the Phase III clinical trial data being derived would not likely be deemed sufficient to support the NDA for Olinvo, the Company would not be able to market Olinvo as soon as it was leading the market to expect, if ever; and (f) as a result of the foregoing, the Company was not on track to achieve the commercial sales revenues from Olinvo as soon as Defendants had led the market to expect during the Class Period, if ever.
To learn more about the Trevena, Inc. class action contact firstname.lastname@example.org.
Dycom Industries, Inc. (DY)
Class Period: November 20, 2017 - August 10, 2018
Lead Plaintiff Deadline: December 24, 2018
Join the action: https://www.zlk.com/pslra-1/dycom-industries-inc-loss-form?wire=3
About the lawsuit: Dycom Industries, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Dycom’s large projects were highly dependent on permitting and tactical considerations, (ii) Dycom was facing great uncertainties related to permitting issues; (iii) said uncertainties would expose Dycom to near-term margin pressure and absorption issues, and (iv) as a result of the foregoing, Defendants’ statements about Dycom’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
To learn more about the Dycom Industries, Inc. class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.